Antibodies Archives

News and Trends 4 Jan 2018

Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic

Alligator Bioscience will receive milestone payments from its partner, Janssen, following the announcement of a combination trial using its cancer antibody. Alligator develops antibodies to fight cancer, and today it has announced that it will receive $6M (€5M) in milestone payments from Janssen. This was triggered by the announcement of a combination trial for its candidate, ADC-1013, which […]

January 4, 2018 - 2 minutesmins - By Alex Dale

News and Trends 14 Dec 2017

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Today, the Belgian biotech has announced that it has raised a very impressive $231M (€195M) following positive results at ASH. The company […]

December 14, 2017 - 1 minutemin - By Alex Dale

News and Trends 11 Dec 2017

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease […]

December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

antibiotic antibody staphylococcus symphogen 1

More News! 30 Nov 2017

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […]

November 30, 2017 - 2 minutesmins - By Alex Dale

Interview 16 Nov 2017

Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates […]

November 16, 2017 - 6 minutesmins - By Alex Dale

tusk therapeutics cancer CD38 immunotherapy 1

News and Trends 14 Nov 2017

British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy

Tusk Therapeutics is working on immunotherapies to ignite the immune system against cancer. The £2.5M grant will help it to accelerate their development. Tusk Therapeutics focuses on immuno-oncology to ‘harness the power’ of the immune system. One of its candidates is an antibody that targets the CD38 immune checkpoint, which is a marker of cell activation that […]

November 14, 2017 - 2 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

Phase I Results are in for Swedish Biotech’s Cancer Antibody

Alligator Bioscience has reported promising results from a Phase I study, where its candidate has been well tolerated in patients with late-stage solid tumors. Alligator Bioscience, located in Lund, Sweden, develops antibody-based immunotherapies to fight cancer. Its pipeline includes clinical and pre-clinical drug candidates, including ADC-1013 and ATOR-1015, as well as novel research candidates. The company […]

November 8, 2017 - 3 minutesmins - By Alex Dale

News and Trends 6 Nov 2017

German Biotech Teams Up with BioNTech to Boost Antibody Development

MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation using its own sophisticated platform. On the back of a highly productive agreement signed in 2013, BioNTech, Europe’s largest privately held biopharma, has moved to agree […]

November 6, 2017 - 1 minutemin - By Alex Dale

dragan grabulovski interview covagen acquisition

Interview 30 Oct 2017

Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014

Dragan Grabulovski co-founded the biotech that became 2014’s largest acquisition in Europe. I caught up with him to hear about the journey and what happens to a founder after his or her company is acquired. Dragan Grabulovski was doing a PhD in pharmaceutical sciences at ETH Zurich in the group of Dario Neri when he […]

October 30, 2017 - 9 minutesmins - By Evelyn Warner

News and Trends 23 Oct 2017

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […]

October 23, 2017 - 3 minutesmins - By Alex Dale

ulf grawunder nbe therapeutics interview

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […]

October 4, 2017 - 5 minutesmins - By Evelyn Warner

Interview 28 Sep 2017

What are Alphabodies and How Do They Drug the Undruggable?

Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […]

September 28, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibodies

Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy

Phase I Results are in for Swedish Biotech’s Cancer Antibody

German Biotech Teams Up with BioNTech to Boost Antibody Development

Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

What are Alphabodies and How Do They Drug the Undruggable?

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!